Related Experiment Video
Updated: Jun 3, 2025
Longitudinal Follow-Up of Urinary Tract Infections and Their Treatment in Mice using Bioluminescence Imaging
Published on: June 14, 2021
Immunoprophylaxis with MV140 Is Effective in the Reduction of Urinary Tract Infections-A Prospective Real-Life Study
Filipe Abadesso Lopes1,2, Miguel Miranda1,2, André Ye1
1Urology Department, Hospital de Santa Maria, 1649-028 Lisbon, Portugal.
Background/Objectives:
Urinary tract infections (UTI) represent a highly frequent and debilitating disease. Immunoactive prophylaxis, such as the polyvalent bacterial whole-cell-based sublingual vaccine MV140, have been developed to avoid antibiotic use. However, the effectiveness of this tool in the Portuguese population is still unknown. This study aims at assessing the effectiveness of treatment with MV140 in a cohort of Portuguese patients presenting with recurrent UTIs.
Methods:
Prospective observational real-life study of 125 patients with complicated and uncomplicated recurrent UTIs treated with MV140. The primary outcome was a reduction in frequency and severity of UTIs after a follow-up of 12 months. Overall satisfaction, adverse events, and assessment of the effectiveness of MV140 in subgroups of patients with specific risk factors for UTIs were secondary outcomes.
Results:
In the 12 months after treatment outset, 38% of patients were UTI-free, 34% reported 1 or 2 UTI episodes, and the remaining 28% presented 3 or more UTIs, corresponding to a mean reduction of 3.20 (2.87-3.53, 95% C.I.; p < 0.001) UTI episodes per year per patient. The effectiveness of MV140 was the same regardless of sex, BMI, regular sexual activity, hypertension, diabetes mellitus, depression, paraplegia, performance of intermittent self-catheterization, indwelling bladder catheter, or previous use of other UTI-preventing vaccines. We observed a higher effectiveness in post-menopausal women compared to pre-menopausal (74.7% vs. 59.4%, respectively, p = 0.029). A total of 73% of patients reported a reduction in symptom severity or days of disease, and the mean global satisfaction was 7.52/10.
Conclusions:
MV140 demonstrated to be effective in the reduction rate of recurrent UTIs in a cohort of adult Portuguese patients.
Insights
The bacterial whole-cell-based sublingual vaccine MV140 effectively reduced recurrent urinary tract infections (UTIs) in Portuguese adults. This immunoactive prophylaxis offers an alternative to antibiotics, showing significant UTI episode reduction and high patient satisfaction.
Area of Science:
- Urology
- Immunology
- Infectious Diseases
Background:
- Urinary tract infections (UTIs) are a common and debilitating condition.
- Antibiotic use for UTIs raises concerns about resistance.
- Immunoactive prophylaxis, like MV140, offers a potential alternative to antibiotics.
Purpose of the Study:
- To assess the effectiveness of the polyvalent bacterial whole-cell-based sublingual vaccine MV140.
- To evaluate MV140 in a cohort of Portuguese patients with recurrent UTIs.
- To determine if MV140 can reduce antibiotic use for UTIs.
Main Methods:
- A prospective observational real-life study was conducted.
- 125 patients with recurrent UTIs received MV140 treatment.
- Outcomes included UTI frequency, severity, patient satisfaction, and adverse events over 12 months.
Main Results:
- 38% of patients were UTI-free after 12 months, with a mean reduction of 3.2 UTI episodes per year.
- MV140 effectiveness was consistent across various risk factors, except for higher efficacy in post-menopausal women.
- 73% of patients reported reduced symptom severity, and mean global satisfaction was 7.52/10.
Conclusions:
- MV140 is effective in reducing the rate of recurrent UTIs in adult Portuguese patients.
- The vaccine demonstrates a favorable safety and satisfaction profile.
- MV140 represents a viable non-antibiotic prophylactic option for recurrent UTIs.
